Kevin Kalinsky, MD, MS, discusses differences in efficacy data for CDK4/6 inhibitors in the treatment of patients with metastatic hormone receptor–positive/HER2-negative breast cancer.
Watch Dr. Kevin Kalisnky, from Winship Cancer Institute of Emory University, discuss treatment for triple-negative disease during the CURE Educated Patient® Breast Cancer Summit at MBCC.
Kevin Kalinsky, MD, MS, discusses genetic sequencing in triple-negative breast cancer, the significance of breast cancer tumor board discussions for informing further research and optimizing patient care, and how future directions in breast cancer treatment are building off the current benefits of drugs classes like antibody-drug conjugates.